Daniel Tasse

Insider profile

Currently holds positions in DBV Technologies SA and Regenxbio Inc

Positions

Position Company Period
Chief Executive Officer, Director DBV Technologies SA March 5, 2019 -
Independent Director Regenxbio Inc Aug. 15, 2016 -
Director Bellerophon Therapeutics Inc Feb. 1, 2014 - May 14, 2019
Chief Executive Officer DBV Technologies SA Nov. 16, 2018 - March 5, 2019
Daniel Tasse's trades of DBV Technologies SA's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Purchase
Price
53.59
Quantity 754
Value €4,227,179
Transaction date
Purchase
Price
119.88
Quantity 39,410 -6.2%
Value US$4,138,992
Transaction date
Purchase
Price
451.35
Quantity 53,894 -11.2%
Value US$1,081,203
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2024-03-12 2024-03-08
B Purchase
754
53.59
€4,227,179 		754 53.59 €4,227,179
2024-03-11 2024-03-08
B Purchase
39,410 -6.2%
119.88
US$4,138,992 		39,410 -6.2% 119.88 US$4,138,992
2015-02-23 2015-02-19
B Purchase
53,894 -11.2%
451.35
US$1,081,203 		53,894 -11.2% 451.35 US$1,081,203